Antipseudomonal treatment decisions during CF exacerbation management

Chronic Pseudomonas aeruginosa in cystic fibrosis (CF) airways has been associated with accelerated lung disease progression [1,2] and increased mortality risk [3,4]. Accordingly, P. aeruginosa garners particular attention when people with CF experience pulmonary exacerbations (PEx), acute periods of increased respiratory signs and symptoms often accompanied by a drop in lung function [5]. For decades, CF PEx treatment guidelines have suggested that two antipseudomonal antimicrobials be included when treating PEx [6], although objective evidence of the clinical benefit of this practice has been lacking [7 –9].

Source: Journal of Cystic Fibrosis - April 21, 2022 Category: Respiratory Medicine Authors: D.R. VanDevanter, N.E. West, D.B. Sanders, M. Skalland, C.H. Goss, P.A. Flume, S.L. Heltshe Source Type: research